Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng-Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter & Andreas Baumann. (2022) Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper. mAbs 14:1.
Read now
Read now
Orla Cunningham, Martin Scott, Zhaohui Sunny Zhou & William J.J. Finlay. (2021) Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns. mAbs 13:1.
Read now
Read now
Shufang Liu, Ashwni Verma, Hubert Kettenberger, Wolfgang F. Richter & Dhaval K. Shah. (2021) Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. mAbs 13:1.
Read now
Read now
Shan Chung, Van Nguyen, Yuwen Linda Lin, Julien Lafrance-Vanasse, Suzie J. Scales, Kevin Lin, Rong Deng, Kathi Williams, Gizette Sperinde, Juan Jenny Li, Kai Zheng, Siddharth Sukumaran, Devin Tesar, James A. Ernst, Saloumeh Fischer, Greg A. Lazar, Saileta Prabhu & An Song. (2019) An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. mAbs 11:5, pages 942-955.
Read now
Read now
Yingda Xu, Dongdong Wang, Bruce Mason, Tony Rossomando, Ning Li, Dingjiang Liu, Jason K Cheung, Wei Xu, Smita Raghava, Amit Katiyar, Christine Nowak, Tao Xiang, Diane D. Dong, Joanne Sun, Alain Beck & Hongcheng Liu. (2019) Structure, heterogeneity and developability assessment of therapeutic antibodies. mAbs 11:2, pages 239-264.
Read now
Read now
William J.J. Finlay, James E. Coleman, Jonathan S. Edwards & Kevin S. Johnson. (2019) Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement. mAbs 11:1, pages 26-44.
Read now
Read now
Nicole M. Piche-Nicholas, Lindsay B. Avery, Amy C. King, Mania Kavosi, Mengmeng Wang, Denise M. O'Hara, Lioudmila Tchistiakova & Madan Katragadda. (2018) Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. mAbs 10:1, pages 81-94.
Read now
Read now
Patrick Koenig, Sarah Sanowar, Chingwei V. Lee & Germaine Fuh. (2017) Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning. mAbs 9:6, pages 959-967.
Read now
Read now
Robyn A. A. Oldham & Jeffrey A. Medin. (2017) Practical considerations for chimeric antigen receptor design and delivery. Expert Opinion on Biological Therapy 17:8, pages 961-978.
Read now
Read now
Miroslav Dostalek, Thomayant Prueksaritanont & Robert F. Kelley. (2017) Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. mAbs 9:5, pages 756-766.
Read now
Read now
Jogender Tushir-Singh. (2017) Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. Expert Opinion on Biological Therapy 17:3, pages 325-338.
Read now
Read now
Yasmina Noubia Abdiche, Rian Harriman, Xiaodi Deng, Yik Andy Yeung, Adam Miles, Winse Morishige, Leila Boustany, Lei Zhu, Shelley Mettler Izquierdo & William Harriman. (2016) Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms. mAbs 8:2, pages 264-277.
Read now
Read now
Amita Datta-Mannan, Arunkumar Thangaraju, Donmienne Leung, Ying Tang, Derrick R Witcher, Jirong Lu & Victor J Wroblewski. (2015) Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. mAbs 7:3, pages 483-493.
Read now
Read now
Kenta Haraya, Tatsuhiko Tachibana, Masahiko Nanami & Masaki Ishigai. (2014) Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica 44:12, pages 1127-1134.
Read now
Read now
Bing Li, Devin Tesar, C Andrew Boswell, Hendry S Cahaya, Anne Wong, Jianhuan Zhang, Y Gloria Meng, Charles Eigenbrot, Homer Pantua, Jinyu Diao, Sharookh B Kapadia, Rong Deng & Robert F Kelley. (2014) Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. mAbs 6:5, pages 1255-1264.
Read now
Read now
Isidro Hötzel, Frank-Peter Theil, Lisa J. Bernstein, Saileta Prabhu, Rong Deng, Leah Quintana, Jeff Lutman, Renuka Sibia, Pamela Chan, Daniela Bumbaca, Paul Fielder, Paul J. Carter & Robert F. Kelley. (2012) A strategy for risk mitigation of antibodies with fast clearance. mAbs 4:6, pages 753-760.
Read now
Read now
Jonathan Moggs, Pierre Moulin, Francois Pognan, Dominique Brees, Michele Leonard, Steve Busch, Andre Cordier, David J Heard, Michael Kammüller, Michael Merz, Page Bouchard & Salah-Dine Chibout. (2012) Investigative safety science as a competitive advantage for Pharma. Expert Opinion on Drug Metabolism & Toxicology 8:9, pages 1071-1082.
Read now
Read now
Yanan Zheng, Devin B. Tesar, Lisa Benincosa, Herbert Birnböck, C. Andrew Boswell, Daniela Bumbaca, Kyra J Cowan, Dimitry M. Danilenko, Ann L. Daugherty, Paul J. Fielder, Hans Peter Grimm, Amita Joshi, Nicole Justies, Gerry Kolaitis, Nicholas Lewin-Koh, Jing Li, Sami McVay, Jennifer O'Mahony, Michael Otteneder, Michael Pantze, Wendy S. Putnam, Zhihua J. Qiu, Jane Ruppel, Thomas Singer, Oliver Stauch, Frank-Peter Theil, Jennifer Visich, Jihong Yang, Yong Ying, Leslie A. Khawli & Wolfgang F. Richter. (2012) Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs 4:2, pages 243-255.
Read now
Read now
Rong Deng, Feng Jin, Saileta Prabhu & Suhasini Iyer. (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?. Expert Opinion on Drug Metabolism & Toxicology 8:2, pages 141-160.
Read now
Read now
Articles from other publishers (52)
Mihaela Kancheva, Lauren Aronson, Tara Pattilachan, Francesco Sautto, Benjamin Daines, Donald Thommes, Angela Shar & Mehdi Razavi. (2023) Bubble-Based Drug Delivery Systems: Next-Generation Diagnosis to Therapy. Journal of Functional Biomaterials 14:7, pages 373.
Crossref
Crossref
Zhongjie Tang, Xiaoyou Wang, Mei Tang, Jin Wu, Jiexuan Zhang, Xinlong Liu, Feiyan Gao, Yu Fu, Peng Tang & Chong Li. (2023) Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy. Advanced Science 10:9.
Crossref
Crossref
Michael W. Leach & Katherine Hammerman. 2023. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology
175
230
.
Pramodkumar P. Gupta, Mala M. Parab, Santosh S. Chhajed & Virupaksha A. Bastikar. 2023. Protein-based Therapeutics. Protein-based Therapeutics
275
296
.
Hannes Ausserwöger, Matthias M. Schneider, Therese W. Herling, Paolo Arosio, Gaetano Invernizzi, Tuomas P. J. Knowles & Nikolai Lorenzen. (2022) Non-specificity as the sticky problem in therapeutic antibody development. Nature Reviews Chemistry 6:12, pages 844-861.
Crossref
Crossref
Gertrudis Rojas. (2022) Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology. Antibodies 11:3, pages 48.
Crossref
Crossref
Priyanka Gupta, Emily K. Makowski, Sandeep Kumar, Yulei Zhang, Justin M. Scheer & Peter M. Tessier. (2022) Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties. Molecular Pharmaceutics 19:3, pages 775-787.
Crossref
Crossref
Xueyin Wang, Lu Min Wong, Michele E. McElvain, Sara Martire, Wen-Hua Lee, Chuck Z. Li, Fernando A. Fisher, Ruchika L. Maheshwari, Ming Lun Wu, Maria C. Imun, Rabi Murad, Dora Toledo Warshaviak, Jun Yin, Alexander Kamb & Han Xu. (2022) A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy. Toxicology and Applied Pharmacology 437, pages 115894.
Crossref
Crossref
Yiming Jin, Megan A. Schladetsch, Xueting Huang, Marcy J. Balunas & Andrew J. Wiemer. (2022) Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics 229, pages 107917.
Crossref
Crossref
Daniela Bumbaca Yadav, Kapil Gadkar & Isabel Figueroa. 2022. Haschek and Rousseaux's Handbook of Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology
77
100
.
J. Deprez, G. Lajoinie, Y. Engelen, S.C. De Smedt & I. Lentacker. (2021) Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery. Advanced Drug Delivery Reviews 172, pages 9-36.
Crossref
Crossref
Brian Geist, Songmao Zheng & Yan Xu. 2021. Remington. Remington
437
462
.
Kip P. Conner, Siva Charan Devanaboyina, Veena A. Thomas & Dan A. Rock. (2020) The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. Pharmacology & Therapeutics 212, pages 107574.
Crossref
Crossref
Jim Freeth & Jo Soden. (2020) New Advances in Cell Microarray Technology to Expand Applications in Target Deconvolution and Off-Target Screening. SLAS Discovery 25:2, pages 223-230.
Crossref
Crossref
Andrew T. Lucas, Ryan Robinson, Allison N. Schorzman, Joseph A. Piscitelli, Juan F. Razo & William C. Zamboni. (2019) Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. Antibodies 8:1, pages 3.
Crossref
Crossref
Rong Deng, C. Andrew Boswell, Wendy S. Putnam, Meina T. Tang, Amit Garg, Chunze Li, Shan Chung & Sandhya Girish. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
151
190
.
Ezra LevyNikolai Slavov. (2018) Single cell protein analysis for systems biology. Essays in Biochemistry 62:4, pages 595-605.
Crossref
Crossref
Frank-Jan Warnders, Marjolijn N. Lub-de Hooge, Elisabeth G. E. de Vries & Jos G. W. Kosterink. (2018) Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non-Ig scaffolds. Medicinal Research Reviews 38:6, pages 1837-1873.
Crossref
Crossref
Heba A. Metwaly, Amal M. El-Gayar & Mamdouh M. El-Shishtawy. (2018) Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats. Archives of Biochemistry and Biophysics 652, pages 50-58.
Crossref
Crossref
Christina L. Zuch de Zafra, Carrie G. Markgraf, David R. Compton & Thomas J. Hudzik. (2018) Abuse liability assessment for biologic drugs – All molecules are not created equal. Regulatory Toxicology and Pharmacology 92, pages 165-172.
Crossref
Crossref
Liming Liu. (2017) Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein & Cell 9:1, pages 15-32.
Crossref
Crossref
Rut Porta, Roberto Borea, Andreia Coelho, Shahanavaj Khan, António Araújo, Pablo Reclusa, Tindara Franchina, Nele Van Der Steen, Peter Van Dam, Jose Ferri, Rafael Sirera, Aung Naing, David Hong & Christian Rolfo. (2017) FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology 113, pages 256-267.
Crossref
Crossref
E. Koch & S. Plassmann. 2017. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development
7
38
.
Claire L. Dobson, Paul W. A. Devine, Jonathan J. Phillips, Daniel R. Higazi, Christopher Lloyd, Bojana Popovic, Joanne Arnold, Andrew Buchanan, Arthur Lewis, Joanne Goodman, Christopher F. van der Walle, Peter Thornton, Lisa Vinall, David Lowne, Anna Aagaard, Lise-Lotte Olsson, Anna Ridderstad Wollberg, Fraser Welsh, Theodoros K. Karamanos, Clare L. Pashley, Matthew G. Iadanza, Neil A. Ranson, Alison E. Ashcroft, Alistair D. Kippen, Tristan J. Vaughan, Sheena E. Radford & David C. Lowe. (2016) Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Scientific Reports 6:1.
Crossref
Crossref
Yi-Fan Zhang & Mitchell Ho. (2016) Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma. Scientific Reports 6:1.
Crossref
Crossref
Amrita V. Kamath. (2016) Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discovery Today: Technologies 21-22, pages 75-83.
Crossref
Crossref
Xiaoyan Xie, Zhiyong Wang, Fangman Chen, Yao Yuan, Jiayi Wang, Rui Liu & Qianming Chen. (2016) Roles of FGFR in oral carcinogenesis. Cell Proliferation 49:3, pages 261-269.
Crossref
Crossref
Jun Zhang & Yang Li. (2016) Therapeutic uses of FGFs. Seminars in Cell & Developmental Biology 53, pages 144-154.
Crossref
Crossref
Lindsay KingCharles Scott Hottenstein, Eric Dobrzynski, Joshua Albert, Jonathan Kehler & Matthew Szapacs. 2016. Current Issues in Ligand Binding Assay Bioanalysis. Current Issues in Ligand Binding Assay Bioanalysis
154
166
.
Jing Wang, Suhasini Iyer, Paul J. Fielder, John D. Davis & Rong Deng. (2015) Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Biopharmaceutics & Drug Disposition 37:2, pages 51-65.
Crossref
Crossref
Peng-Hui Hu, Lan-Hong Pan, Patrick Ting-Yat Wong, Wen-Hui Chen, Yan-Qing Yang, Hong Wang, Jun-Jian Xiang & Meng Xu. (2016)
125
I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma
. World Journal of Gastroenterology 22:21, pages 5033.
Crossref
Crossref
Thierry Flandre, Sarah Taplin, Stewart Jones & Peter Lloyd. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
14
.
Tatsuhiko Tachibana, Kenta Haraya, Yuki Iwayanagi & Tomoyuki Igawa. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
13
.
Weirong Wang & Thomayant Prueksaritanont. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
11
.
Sue TownsendBrian J. FennellJames R. ApgarMatthew LambertBarry McDonnellJoanne GrantJason WadeEdward FranklinNiall FoyDeirdre Ní ShúilleabháinConor FieldsAlfredo Darmanin-SheehanAmy KingJanet E. PaulsenTimothy P. Hickling, Lioudmila TchistiakovaOrla CunninghamWilliam J. J. Finlay. (2015) Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies. Proceedings of the National Academy of Sciences 112:50, pages 15354-15359.
Crossref
Crossref
Daniela Bumbaca Yadav, Vikas K. Sharma, Charles Andrew Boswell, Isidro Hotzel, Devin Tesar, Yonglei Shang, Yong Ying, Saloumeh K. Fischer, Jane L. Grogan, Eugene Y. Chiang, Konnie Urban, Sheila Ulufatu, Leslie A. Khawli, Saileta Prabhu, Sean Joseph & Robert F. Kelley. (2015) Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. Journal of Biological Chemistry 290:50, pages 29732-29741.
Crossref
Crossref
Dhaval K. Shah. (2015) Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. Journal of Pharmacokinetics and Pharmacodynamics 42:5, pages 553-571.
Crossref
Crossref
Mark Zanin, Zhen-Yong Keck, G. Jonah Rainey, Chia-Ying Kao Lam, Adrianus C. M. Boon, Adam Rubrum, Daniel Darnell, Sook-San Wong, Yolanda Griffin, Jinming Xia, Robert G. Webster, Richard Webby, Syd Johnson & Steven Foung. (2015) An Anti-H5N1 Influenza Virus FcDART Antibody Is a Highly Efficacious Therapeutic Agent and Prophylactic against H5N1 Influenza Virus Infection. Journal of Virology 89:8, pages 4549-4561.
Crossref
Crossref
Lawrence M. Kauvar, Keyi Liu, Minha Park, Neal DeChene, Robert Stephenson, Edgar Tenorio, Stote L. Ellsworth, Takako Tabata, Matthew Petitt, Mitsuru Tsuge, June Fang-Hoover, Stuart P. Adler, Xiaohong Cui, Michael A. McVoy & Lenore Pereira. (2015) A High-Affinity Native Human Antibody Neutralizes Human Cytomegalovirus Infection of Diverse Cell Types. Antimicrobial Agents and Chemotherapy 59:3, pages 1558-1568.
Crossref
Crossref
Koos Koole, Pauline M.W. van Kempen, Liselotte W. van Bockel, Timo Smets, Zoë van der Klooster, Annemiek C. Dutman, Ton Peeters, Ron Koole, Paul van Diest, Robert J.J. van Es & Stefan M. Willems. (2015) FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma. Pathobiology 82:6, pages 280-289.
Crossref
Crossref
Mohamed M Darweish, Ahmed Abbas, Mohamed A Ebrahim & Mohammed M H Al-Gayyar. (2014) Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway. Journal of Pharmacy and Pharmacology 66:7, pages 1032-1045.
Crossref
Crossref
R. Dienstmann, J. Rodon, A. Prat, J. Perez-Garcia, B. Adamo, E. Felip, J. Cortes, A.J. Iafrate, P. Nuciforo & J. Tabernero. (2014) Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Annals of Oncology 25:3, pages 552-563.
Crossref
Crossref
Sven Kronenberg, Andreas Baumann, Lolke de Haan, Heather J. Hinton, Jonathan Moggs, Frank-Peter Theil, Ian Wakefield & Thomas Singer. (2013) Current challenges and opportunities in nonclinical safety testing of biologics. Drug Discovery Today 18:23-24, pages 1138-1143.
Crossref
Crossref
Karen D. Price & Gautham K. Rao. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
303
342
.
Padma Kumar Narayanan, Rafael Ponce & Beth Hinkle. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
65
95
.
Lubna Abuqayyas & Joseph P. Balthasar. (2012) Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. International Journal of Pharmaceutics 439:1-2, pages 8-16.
Crossref
Crossref
Elton P. Hudson, Mathias Uhlen & Johan Rockberg. (2012) Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes. Scientific Reports 2:1.
Crossref
Crossref
Thomayant Prueksaritanont & Cuyue Tang. (2012) ADME of Biologics—What Have We Learned from Small Molecules?. The AAPS Journal 14:3, pages 410-419.
Crossref
Crossref
Yan Xin, Shuang Bai, Lisa A. Damico-Beyer, Denise Jin, Wei-Ching Liang, Yan Wu, Frank-Peter Theil, Amita Joshi, Yanmei Lu, John Lowe, Mauricio Maia, Rainer K. Brachmann & Hong Xiang. (2012) Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans. Pharmaceutical Research 29:9, pages 2512-2521.
Crossref
Crossref
Michael J. Santostefano, Jacqueline Kirchner, Christine Vissinga, Madeline Fort, Sean Lear, Wei-Jian Pan, Peter J. Prince, Kelly M. Hensley, Duc Tran, Dan Rock, Hugo M. Vargas, Padma Narayanan, Remi Jawando, William Rees, James F. Reindel, Kai Reynhardt & Nancy Everds. (2012) Off-Target Platelet Activation in Macaques Unique to a Therapeutic Monoclonal Antibody. Toxicologic Pathology 40:6, pages 899-917.
Crossref
Crossref
Daniela Bumbaca, Hong Xiang, C Andrew Boswell, Ruediger E Port, Shannon L Stainton, Eduardo E Mundo, Sheila Ulufatu, Anil Bagri, Frank-Peter Theil, Paul J Fielder, Leslie A Khawli & Ben-Quan Shen. (2012) Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. British Journal of Pharmacology 166:1, pages 368-377.
Crossref
Crossref
A. Nigel Brooks, Elaine Kilgour & Paul D. Smith. (2012) Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer. Clinical Cancer Research 18:7, pages 1855-1862.
Crossref
Crossref